bortezomib sold brand name velcade among others anticancer medication used treat multiple myeloma mantle cell includes multiple myeloma previously received generally used together given common side effects include nausea diarrhea tiredness low platelets fever numbness low white blood cells shortness breath rash abdominal severe side effects include low blood pressure tumour lysis syndrome heart failure reversible posterior leukoencephalopathy class medications known proteasome works inhibiting proteasomes cellular complexes break bortezomib approved medical use united states european union world health organizations list essential available generic two openlabel trials established efficacy bortezomib without dexamethasone days cycle maximum eight cycles heavily pretreated people relapsedrefractory multiple phase iii demonstrated superiority bortezomib highdose dexamethasone regimen eg median ttp vs months survival vs new studies show bortezomib may potentially help recover vincristine treatment treating acute lymphoblastic leukemia replacing vincristine bortezomib also evaluated together drugs treatment multiple myelomas adults seen bortezomib plus lenalidomide plus dexamethasone well bortezomib plus melphalan prednisone may result large increase progressionfree gastrointestinal effects asthenia common adverse bortezomib associated peripheral neuropathy people resulting pain worse people preexisting neuropathy addition myelosuppression causing neutropenia thrombocytopenia also occur doselimiting however side effects usually mild relative bone marrow transplantation treatment options people advanced disease bortezomib associated high rate although prophylactic acyclovir reduce risk ocular side effects chalazion hordeolum stye may common women led discontinuation acute interstitial nephritis also polyphenols derived green tea extract including epigallocatechin gallate egcg expected synergistic effect instead found reduce effectiveness bortezomib cell culture drug nprotected dipeptide written pyzpheboroleu stands pyrazinoic acid phenylalanine leucine boronic acid instead carboxylic acid boron atom bortezomib binds catalytic site high affinity specificity normal cells proteasome regulates protein expression function degradation ubiquitylated proteins also rids cell abnormal misfolded proteins clinical preclinical data support role proteasome maintaining immortal phenotype myeloma cells cellculture xenograft data support similar function solid tumor cancers multiple mechanisms likely involved proteasome inhibition may prevent degradation proapoptotic factors thereby triggering programmed cell death neoplastic cells recently found bortezomib caused rapid dramatic change levels intracellular peptides produced intracellular peptides shown biologically active effect bortezomib levels intracellular peptides may contribute biological andor side effects drug subcutaneous administration peak plasma levels nm peak sustained hrs intravenous injection peak plasma levels nm minutes levels rapidly drop drug distributes tissues volume distribution routes provide equal drug exposures generally comparable therapeutic efficacy elimination half life hours drug primarily cleared hepatic pharmacodynamics bortezomib determined quantifying proteasome inhibition peripheral blood mononuclear cells taken people receiving drug bortezomib originally made myogenics drug tested small phase clinical trial people multiple myeloma brought clinical trials millennium pharmaceuticals october may seven years initial synthesis bortezomib marketed velcade millennium pharmaceuticals inc approved united states food drug administration fda use multiple myeloma based results summit phase ii bortezomib approved united states initial treatment people multiple bortezomib previously approved treatment people multiple myeloma received least one prior therapy treatment refractory multiple approval based international multicenter open label activecontrol trial previously untreated people symptomatic multiple people randomized receive either nine cycles oral melphalan plus prednisone p mp plus people received plus prednisone daily four days every weeks mp schedule bortezomib iv days every week cycle cycles weekly weeks time progression ttp primary efficacy overall survival os progressionfree survival pfs response rate rr secondary eligible people age total people randomized receive mp combination bortezomib plus demographics baseline disease characteristics similar two trial stopped following prespecified interim analysis showing statistically significant improvement ttp addition bortezomib mp median months compared mp median months hr ci p os pfs rr also significantly superior bortezomibmp august bortezomib approved united states retreatment adults multiple previously responded velcade therapy relapsed least six months following completion prior october bortezomib approved united states treatment treatmentna√Øve people mantle cell lymphoma uk nice initially recommended velcade october due cost per person studies reviewed nice reported could extend life expectancy average six months standard however company later proposed performancelinked cost reduction multiple httpsenwikipediaorgwikibortezomib